Unicycive Therapeutics & United States — Food and Drug Administration

Unicycive Therapeutics: Unicycive Therapeutics is facing a federal securities class action lawsuit due to allegedly making false and misleading statements regarding its manufacturing compliance and regulatory prospects for OLC NDA, which led to significant stock price drops.

Unicycive Therapeutics: Unicycive Therapeutics is being sued for allegedly issuing materially false and/or misleading statements regarding its readiness to satisfy FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application.

Unicycive Therapeutics: Unicycive Therapeutics is the defendant in a class action lawsuit alleging false and misleading statements regarding its manufacturing compliance and regulatory prospects for oxylanthanum carbunate (OLC). This event negatively impacts Unicycive Therapeutics's reputation and stock price.